Role of ascorbic acid in children with first presentation Immune thrombocytopenic purpura .A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511587894799

Enrollment

150

Registered

2025-11-21

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders

Interventions

Vitamin C

Standard steroid therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of ITP by clinical examination and laboratory investigations Acute ITP Patients with a platelet count less than 30 x?10?^9/L or platelet count less than 50 ×?10?^9 /L in presence of bleeding Age 1-12 years Both sexes (males and females) Parents giving willingly informed consents

Exclusion criteria

Exclusion criteria: 1. Patient with non immune thrombocytopenia. 2. Patients with Previous attack of ITP: persistent and chronic ITP 3. Patients presenting with no or mild bleeding (defined as skin manifestations only, such as bruising and petechiae) 4. Patients with life threatening bleeding : massive bleeding causing hemoglobin drop >2gm/dL or CNS bleeding

Design outcomes

Primary

Measure	Time frame
The impact of vitamin C on the platelet count	—

Secondary

Measure	Time frame
Impact of vitamin C on the bleeding severity	—

Countries

Egypt

Contacts

Public ContactHoda Atef Abdelsattar Ibrahim

Cairo University

hodaibrahim424@gmail.com01116344417

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026